CJC-1295 with DAC results: what to expect and when

An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.

Also called: CJC-1295 DAC, DAC:GRF, DAC-GRF.

GHRH analogues · Long-acting GHRH receptor agonist with an albumin-binding tag.

Three small published studies and one stopped HIV trial. A protein report reused participants; health benefits remain unproven.

Key studies

  • Teichman 2006: one dose: One DAC injection raised GH and IGF-1 for days; it did not test muscle gain, fat loss or recovery. (source)
  • Teichman 2006: repeat doses: Weekly or fortnightly DAC dosing accumulated and kept IGF-1 elevated; long-term outcomes were not tested. (source)
  • Ionescu 2006: GH pulses: DAC preserved detectable GH pulses while raising the trough; this does not prove safety of sustained stimulation. (source)
  • Sackmann-Sala 2009: blood proteins: An exploratory analysis found possible hormone-response markers, not better health or performance. (source)
  • HIV visceral-fat trial: terminated: The terminated study supplies no usable benefit estimate or established safe weekly maximum. (source)
  • Jetté 2005: albumin binding: Animal and cell work supports a long-lasting GHRH analogue; it does not validate community products. (source)

Related to CJC-1295 with DAC

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.